한글목차

저분자 주사제 시장 규모는 최근 급성장하고 있습니다. 2025년 2,459억 7,000만 달러에서 2026년에는 2,763억 달러에 이르고, CAGR 12.3%의 성장이 전망되고 있습니다. 지난 수년간의 성장은 만성질환 유병률 증가, 주사제 치료의 보급 확대, 약물 제제 기술의 발전, 병원 인프라 확충, 감염관리에 대한 인식 개선 등이 요인으로 꼽힙니다.

저분자 주사제 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 4,123억 5,000만 달러에 이르고, CAGR은 10.5%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 개인 맞춤형 의료에 대한 수요 증가, 종양학 및 항바이러스 치료의 확대, 약물 전달 시스템의 기술 발전, 재택치료 및 외래 서비스 확대, 생물학적 제제 및 병용 요법에 대한 투자 증가 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 주사제를 통한 약물 전달에 대한 선호도 향상, 병원 및 클리닉의 정맥주사 서비스 확대, 표적 화학요법 치료 증가, 항바이러스 저분자 약물의 성장, 저분자량 약물 제제에 대한 수요 증가 등을 꼽을 수 있습니다.

향후 몇 년 동안 만성질환의 유병률 증가가 저분자 주사제 시장의 성장을 견인할 것으로 예측됩니다. 만성질환이란 장기간 지속되고 일반적으로 완만하게 진행되는 병태를 말합니다. 만성질환 증가는 좌식 생활습관, 부적절한 식습관, 흡연, 스트레스 수준 증가 등의 요인에 기인합니다. 이러한 생활습관 요인은 비만, 당뇨병, 심혈관 질환, 특정 암과 같은 병태의 발병에 기여하고 있습니다. 저분자 주사제는 표적치료제 제공, 환자 순응도 향상, 질병 조절, 병용요법 옵션 제공, 치료 모니터링 가능 등을 통해 만성질환 관리에서 가치를 발휘합니다. 예를 들어, 2024년 6월 영국 정부 기관인 국민보건서비스(NHS)는 일반의(GP)에 등록된 3,615,330명이 비당뇨병성 고혈당 또는 전당뇨병(당뇨병 임계치에 도달하지 않은 고혈당 상태)으로 진단받았다고 보고했습니다. 이는 2022년 306만 5,825건에서 18% 증가한 수치입니다. 이처럼 만성질환의 유병률 증가가 저분자 주사제 시장의 성장을 가속하고 있습니다.

저분자 주사제 시장의 주요 기업들은 치료 효과와 환자 예후를 개선하기 위해 병용요법 등 혁신적인 솔루션 개발에 주력하고 있습니다. 병용요법은 두 가지 이상의 약물을 병용하여 효과를 높이고 내성을 최소화하거나 질환의 다른 측면에 대처하기 위한 치료 전략입니다. 예를 들어, 2025년 11월 미국 바이오 제약사 애브비는 재발성 또는 난치성 여포성 림프종(FL) 성인 환자를 위한 리툭시맙 및 레날리도미드 병용요법 치료제 '엡킨리(Epkynly, 성분명: 엡코리타마부비주)'의 미국 식품의약국(FDA) 승인을 획득했습니다. 의약품국(FDA) 승인을 획득했습니다. 이 약은 인간화 이중특이적 IgG1 항체로서 T세포의 CD3 수용체와 B세포(악성 림프종 세포 포함)의 CD20 수용체를 동시에 표적으로 하여 T세포를 활성화시켜 암성 B세포를 표적으로 제거합니다. 화학요법 없이 피하 투여하는 치료 옵션으로 재발성 또는 난치성 여포성 림프종에 리툭시맙 및 레날리도마이드와 병용 투여하는 것을 목표로 합니다. EPKINLY는 효율적인 T세포 활성화와 지속적인 림프종 세포 제거를 촉진하는 새로운 면역 중재적 접근법을 제공하며, 고정된 기간의 요법으로 외래에서 편리하게 치료할 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Small molecule injectable drugs are pharmaceutical compounds characterized by their small size and low molecular weight. These medications are commonly administered through injections-intravenously, intramuscularly, or subcutaneously-to ensure systemic distribution throughout the body.

The main types of drug classes in small-molecule injectable drugs include small-molecule antibiotics, analgesics, chemotherapy, antivirals, anticoagulants, skeletal muscle relaxants, anticonvulsants, and others. Small-molecule antibiotics are antibacterial agents with low molecular weight and simple chemical structures. The various indications include pain management, oncology, infectious diseases, cardiovascular diseases, CNS disorders, and others. The different delivery types include IV sets, intravenous injections, infusion pumps, intramuscular injections, and subcutaneous injections, which are used by various end-users such as hospitals, ambulatory clinics, outpatient facilities, infusion therapy centers, home care, and others.

Tariffs have impacted the small molecule injectable drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and manufacturing equipment, causing disruptions in global supply chains. The segments most affected include chemotherapy and antiviral drugs, particularly in regions like Asia-Pacific and North America, which are major production and export hubs. Some positive effects include encouraging local manufacturing and innovation in cost-effective formulations, helping companies diversify sourcing strategies and improve supply chain resilience.

The small molecule injectable drugs market research report is one of a series of new reports from The Business Research Company that provides small molecule injectable drugs market statistics, including small molecule injectable drugs industry global market size, regional shares, competitors with a small molecule injectable drugs market share, detailed small molecule injectable drugs market segments, market trends and opportunities, and any further data you may need to thrive in the small molecule injectable drugs industry. This small molecule injectable drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The small molecule injectable drugs market size has grown rapidly in recent years. It will grow from $245.97 billion in 2025 to $276.3 billion in 2026 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, growing adoption of injectable therapeutics, advances in drug formulation technologies, expansion of hospital infrastructure, rising awareness of infection management.

The small molecule injectable drugs market size is expected to see rapid growth in the next few years. It will grow to $412.35 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to rising demand for personalized medicine, growth in oncology and antiviral treatments, technological advancements in drug delivery systems, expansion of home care and outpatient services, increasing investment in biologics and combination therapies. Major trends in the forecast period include increasing preference for injectable drug delivery, expansion of hospital and clinic infusion services, rise in targeted chemotherapy treatments, growth in antiviral small molecule drugs, demand for low molecular weight drug formulations.

The increasing prevalence of chronic diseases is expected to drive the growth of the small-molecule injectable drug market in the coming years. Chronic diseases are conditions that persist over the long term and generally progress slowly. The rise in chronic diseases is attributed to factors such as sedentary lifestyles, poor dietary habits, tobacco consumption, and elevated stress levels. These lifestyle factors contribute to the development of conditions including obesity, diabetes, cardiovascular diseases, and certain cancers. Small-molecule injectable drugs are valuable in managing chronic diseases by providing targeted therapy, enhancing patient compliance, enabling disease modification, offering combination therapy options, and allowing therapeutic monitoring. For example, in June 2024, the National Health Service, a UK-based government organization, reported that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels that does not meet the threshold for diabetes) in 2023, representing an 18% increase from 3,065,825 cases in 2022. Thus, the growing prevalence of chronic diseases fuels the small-molecule injectable drug market.

Major companies in the small-molecule injectable drug market are concentrating on developing innovative solutions such as combination regimens to improve efficacy and patient outcomes. A combination regimen is a treatment strategy that employs two or more drugs together to enhance effectiveness, minimize resistance, or address different facets of a disease. For example, in November 2025, AbbVie Inc., a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide for treating adult patients with relapsed or refractory follicular lymphoma (FL). It is a humanized bispecific IgG1 antibody that simultaneously targets the CD3 receptor on T cells and the CD20 receptor on B cells, including malignant lymphoma cells, to engage and activate T cells for the targeted elimination of cancerous B cells. It is administered subcutaneously as a chemotherapy-free treatment option and is intended to be used alongside rituximab and lenalidomide for relapsed or refractory follicular lymphoma. EPKINLY provides a novel immune-mediated approach that facilitates efficient T-cell activation and durable lymphoma cell depletion, offering a convenient outpatient therapy with a fixed-duration regimen.

In April 2023, Delpharm SAS, a France-based drug developer and contract manufacturer, acquired Leiden Development Centre in the Netherlands from Dr. Reddy's Laboratories for an undisclosed amount. This acquisition supports Delpharm's strategy to broaden its pharmaceutical development services, especially in the field of injectable formulations. Delpharm aims to offer a one-stop shop service for clients seeking to develop injectable drugs, thereby accelerating patient access to new medicines. Dr. Reddy's Laboratories is an India-based pharmaceutical company providing small-molecule injectable drug formulations through the Leiden Development Center.

Major companies operating in the small molecule injectable drugs market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, Fresenius Kabi AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals plc, BioCryst Pharmaceuticals Inc., Mylan N.V.

North America was the largest region in the small molecule injectable drugs market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the small molecule injectable drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the small molecule injectable drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The small molecule injectable drugs market consists of sales of antineoplastic agents, hormones, and vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Small Molecule Injectable Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses small molecule injectable drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for small molecule injectable drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The small molecule injectable drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Small Molecule Antibiotics; Analgesics; Chemotherapy; Antivirals; Anticoagulant; Skeletal Muscle Relaxants; Anticonvulsants; Other Drug Class
• 2) By Indication: Pain Management; Oncology; Infectious Diseases; Cardiovascular Diseases; CNS Diseases; Other Indications
• 3) By Mode of Delivery: IV Set; Intravenous Injection; Infusion Pump; Intramuscular Injection; Subcutaneous Injection
• 4) By End User: Hospitals; Ambulatory Clinics; Outpatient Facility; Infusion Therapy Center; Home Care; Other End Users
• Subsegments:
• 1) By Small Molecule Antibiotics: Penicillin-Based Antibiotics; Cephalosporins; Aminoglycosides; Macrolides; Tetracyclines
• 2) By Analgesics: Nonsteroidal Anti-inflammatory Drugs (NSAIDs); Opioids; Acetaminophen
• 3) By Chemotherapy: Alkylating Agents; Antimetabolites; Mitotic Inhibitors; Topoisomerase Inhibitors
• 4) By Antivirals: Nucleoside Analogues; Protease Inhibitors; Reverse Transcriptase Inhibitors
• 5) By Anticoagulant: Heparin; Low Molecular Weight Heparins
• 6) By Skeletal Muscle Relaxants: Baclofen; Methocarbamol
• 7) By Anticonvulsants: Benzodiazepines; Phenytoin
• 8) By Other Drug Class: Immunosuppressants; Hormonal Therapies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; Abbott Laboratories; Novartis AG; Fresenius Kabi AG; GlaxoSmithKline plc; Eli Lilly and Company; Gilead Sciences Inc.; Amgen Inc.; Becton Dickinson and Company; Teva Pharmaceutical Industries Ltd.; Baxter International Inc.; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma Ltd.; Dr. Reddy's Laboratories Ltd.; Cipla Limited; Hikma Pharmaceuticals plc; BioCryst Pharmaceuticals Inc.; Mylan N.V.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Small Molecule Injectable Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Small Molecule Injectable Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Small Molecule Injectable Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Small Molecule Injectable Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Increasing Preference for Injectable Drug Delivery
  • 4.2.2 Expansion of Hospital and Clinic Infusion Services
  • 4.2.3 Rise in Targeted Chemotherapy Treatments
  • 4.2.4 Growth in Antiviral Small Molecule Drugs
  • 4.2.5 Demand for Low Molecular Weight Drug Formulations

5. Small Molecule Injectable Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Ambulatory Clinics
• 5.3 Outpatient Facilities
• 5.4 Infusion Therapy Centers
• 5.5 Home Care

6. Small Molecule Injectable Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Small Molecule Injectable Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Small Molecule Injectable Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Small Molecule Injectable Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Small Molecule Injectable Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Small Molecule Injectable Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Small Molecule Injectable Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Small Molecule Injectable Drugs Market Segmentation

• 9.1. Global Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Small Molecule Antibiotics, Analgesics, Chemotherapy, Antivirals, Anticoagulant, Skeletal Muscle Relaxants, Anticonvulsants, Other Drug Class
• 9.2. Global Small Molecule Injectable Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pain Management, Oncology, Infectious Diseases, Cardiovascular Diseases, CNS Diseases, Other Indications
• 9.3. Global Small Molecule Injectable Drugs Market, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• IV Set, Intravenous Injection, Infusion Pump, Intramuscular Injection, Subcutaneous Injection
• 9.4. Global Small Molecule Injectable Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Ambulatory Clinics, Outpatient Facility, Infusion Therapy Center, Home Care, Other End Users
• 9.5. Global Small Molecule Injectable Drugs Market, Sub-Segmentation Of Small Molecule Antibiotics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Penicillin-Based Antibiotics, Cephalosporins, Aminoglycosides, Macrolides, Tetracyclines
• 9.6. Global Small Molecule Injectable Drugs Market, Sub-Segmentation Of Analgesics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Opioids, Acetaminophen
• 9.7. Global Small Molecule Injectable Drugs Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Alkylating Agents, Antimetabolites, Mitotic Inhibitors, Topoisomerase Inhibitors
• 9.8. Global Small Molecule Injectable Drugs Market, Sub-Segmentation Of Antivirals, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Nucleoside Analogues, Protease Inhibitors, Reverse Transcriptase Inhibitors
• 9.9. Global Small Molecule Injectable Drugs Market, Sub-Segmentation Of Anticoagulant, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Heparin, Low Molecular Weight Heparins
• 9.10. Global Small Molecule Injectable Drugs Market, Sub-Segmentation Of Skeletal Muscle Relaxants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Baclofen, Methocarbamol
• 9.11. Global Small Molecule Injectable Drugs Market, Sub-Segmentation Of Anticonvulsants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Benzodiazepines, Phenytoin
• 9.12. Global Small Molecule Injectable Drugs Market, Sub-Segmentation Of Other Drug Class, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Immunosuppressants, Hormonal Therapies

10. Small Molecule Injectable Drugs Market Regional And Country Analysis

• 10.1. Global Small Molecule Injectable Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Small Molecule Injectable Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Small Molecule Injectable Drugs Market

• 11.1. Asia-Pacific Small Molecule Injectable Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Small Molecule Injectable Drugs Market

• 12.1. China Small Molecule Injectable Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Small Molecule Injectable Drugs Market

• 13.1. India Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Small Molecule Injectable Drugs Market

• 14.1. Japan Small Molecule Injectable Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Small Molecule Injectable Drugs Market

• 15.1. Australia Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Small Molecule Injectable Drugs Market

• 16.1. Indonesia Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Small Molecule Injectable Drugs Market

• 17.1. South Korea Small Molecule Injectable Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Small Molecule Injectable Drugs Market

• 18.1. Taiwan Small Molecule Injectable Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Small Molecule Injectable Drugs Market

• 19.1. South East Asia Small Molecule Injectable Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Small Molecule Injectable Drugs Market

• 20.1. Western Europe Small Molecule Injectable Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Small Molecule Injectable Drugs Market

• 21.1. UK Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Small Molecule Injectable Drugs Market

• 22.1. Germany Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Small Molecule Injectable Drugs Market

• 23.1. France Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Small Molecule Injectable Drugs Market

• 24.1. Italy Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Small Molecule Injectable Drugs Market

• 25.1. Spain Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Small Molecule Injectable Drugs Market

• 26.1. Eastern Europe Small Molecule Injectable Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Small Molecule Injectable Drugs Market

• 27.1. Russia Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Small Molecule Injectable Drugs Market

• 28.1. North America Small Molecule Injectable Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Small Molecule Injectable Drugs Market

• 29.1. USA Small Molecule Injectable Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Small Molecule Injectable Drugs Market

• 30.1. Canada Small Molecule Injectable Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Small Molecule Injectable Drugs Market

• 31.1. South America Small Molecule Injectable Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Small Molecule Injectable Drugs Market

• 32.1. Brazil Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Small Molecule Injectable Drugs Market

• 33.1. Middle East Small Molecule Injectable Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Small Molecule Injectable Drugs Market

• 34.1. Africa Small Molecule Injectable Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Small Molecule Injectable Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Mode of Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Small Molecule Injectable Drugs Market Regulatory and Investment Landscape

36. Small Molecule Injectable Drugs Market Competitive Landscape And Company Profiles

• 36.1. Small Molecule Injectable Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Small Molecule Injectable Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Small Molecule Injectable Drugs Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Small Molecule Injectable Drugs Market Other Major And Innovative Companies

• Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, Fresenius Kabi AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd.

38. Global Small Molecule Injectable Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Small Molecule Injectable Drugs Market

40. Small Molecule Injectable Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Small Molecule Injectable Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Small Molecule Injectable Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Small Molecule Injectable Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer